A revolutionary approach to GLP-1s and obesity care.
Noom Med, our powerful obesity care solution—now with SmartRx—combines biology and psychology to deliver better outcomes and lower overall costs. With a proven 4.1x ROI and SmartRx further enhancing ROI, Noom Med drives long-term success for both individuals and organizations.

Affordable GLP-1 access with a breakthrough pharmacy solution.
While GLP-1s have revolutionized healthcare, they come at a cost. Noom’s SmartRx pharmacy carve-out solution, an enhancement of Noom Med, provides transparent, discounted pricing on GLP-1 medications for weight loss, with the flexibility to set custom copays separate from other covered medications.

Bypass PBM intermediaries for cost-effective, uninterrupted medication access

Access branded GLP-1 medications at reduced prices and decide how to share costs with employees

Ensure rapid access to GLP-1 medications within 5 days to drive increased persistence and better health outcomes
Higher ROI. Better outcomes. Healthier people.
Based in cognitive science, Noom Med delivers maintainable outcomes through evidence-based obesity care that combines sustainable lifestyle changes with medication-assisted weight loss as needed, ultimately maximizing ROI.

Evidence-based protocols
Proven experience showing that while GLP-1 medications are an effective tool for weight management, their efficacy is significantly enhanced when paired with robust lifestyle interventions.
Reducing the yo-yo effect
A structured approach to medication tapering that begins with medication support, and balances medical needs and costs to avoid weight regain as part of the “yo-yo” cycle.
World class behavior change
We utilize our award-winning behavior change program as the foundation of our care model to enhance health outcomes and ensure lasting ROI.
Positive ROI accumulation
A proven track record of delivered, measurable health improvements and cost savings, providing partners with a 4.1X ROI over a three-year period.
Combining mind and medicine, for lasting health outcomes.




Real support leads to real results.
Proven outcomes in 50+ peer-reviewed publications and 10+ academic medical research collaborations.
55%
are expected to start with an alternative to GLP-1s1
1.4X
more weight loss reported when pairing Noom with an early GLP-1 vs a GLP-1 alone2
4.1X
projected ROI in healthcare and cost savings over 3 years3
The proof is in the members.
-

The Next Evolution in Healthcare Benefits
White Paper Benefit planning -

6 Healthcare Trends Shaping the Benefits Landscape
Blog Benefit planning -

Breaking Down the Metabolic Health Domino Effect
Blog Benefit planning
The all-in-one solution to healthy living and lower costs.
Bring Noom to your organization today.
- Third-party validated actuarial analysis, October 2024. This projection is based on a comparison to a status quo scenario where GLP-1 medication spending is uncontrolled. ROI may vary based on factors such as company size, employee health profiles, and current healthcare costs.
- Based on a retrospective study of self-reported data of pounds lost for active versus passive users who were offered the Noom program when being prescribed an early stage GLP-1.
- Third-party validated actuarial analysis, October 2024. This projection is based on a comparison to a status quo scenario where GLP-1 medication spending is uncontrolled. ROI may vary based on factors such as company size, employee health profiles, and current healthcare costs.